Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: james who wrote (1344)	12/4/1997 2:29:00 PM
From: tom jones	Read Replies (2) \| Respond to of 4676

To james and all: Recomendations for ISIP are worth nothing right now, as stated by others on this board. Very good news about 2922 (Isis says news will be early 1998 now) or 2302 will help move this stock. I am waiting for the good news to buy more ISIP because the news could be bad. Only a buyout will make ISIP price jump. There was to be news about Isis 2302 phase II trials in 1997 but there doesn't seem to be any coming and they delayed the Isis 2922 phase III trial end news (or the end of the trial) also. They seem to be shifting their emphasis to cancer drugs now. If the 2302's and 2922 drugs do not pan out it is going to set Isis way back in time and stock price. Comments? Tom